Taysha Gene Therapies, Inc. (TSHA)

Taysha Gene Therapies, Inc. is trading at $4.14, down 7.80% on the session. The 50 day average sits at $5.50 and the 200 day at $5.43, which puts the stock in a uptrend. RSI is at 33.1, which reads as weak, and MACD is bearish crossover. Volume is above average.

The nearest support is around $4.26 with resistance near $5.46, so that band frames the current range. Average daily movement is roughly $0.25, or about 6.1% of the share price, which is what any stop placement has to allow for. The overall health score of 35 out of 100 combines a trend score of 33, momentum of 22 and a risk score of 58.

Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.